{"url_path":"/sec/ptct/8-k/2026-06-09/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 ****Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-09","source_url":"https://www.sec.gov/Archives/edgar/data/1070081/0001104659-26-071916-index.html","accession_number":"0001104659-26-071916","cik":"0001070081","ticker":"PTCT","issuer_name":"PTC THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1070081/0001104659-26-071916-index.html","primary_entity_key":"0001070081","primary_entity_name":"PTC THERAPEUTICS, INC."},"word_count":179,"has_tables":true,"body_markdown":"**Item 5.02. ****Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**\n\nOn June 8, 2026, Alethia Young, a member of the board of directors (the “Board”) of PTC Therapeutics, Inc. (the “Company”), notified the Company of her resignation from the Board effective June 8, 2026. Ms. Young has informed the Company that her decision is based on her need to focus on commitments to her other work activities and was not due to any disagreement with the Company.\n\nThe Company and Ms. Young entered into a consulting agreement effective as of June 8, 2026 (the “Consulting Agreement”) pursuant to which Ms. Young will remain as an advisor to the Company, with a term continuing through June 8, 2027. Pursuant to the Consulting Agreement, Ms. Young will receive a monthly consulting fee of $4,166.67.\n\nThe foregoing description of the Consulting Agreement is qualified in its entirety by reference to the full text of the Consulting Agreement, a copy of which is attached hereto as Exhibit 10.1 and incorporated herein by reference."}